All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-02-15T10:08:33.000Z

ASH 2018 | Practice changing abstracts in multiple myeloma

Bookmark this article

Did you miss ASH 2018? The Multiple Myeloma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across multiple myeloma (MM).

Our selection of ASH abstracts includes comments from the MM Hub Steering Committee on the key phase III clinical trials presented during ASH, such as TOURMALINE-MM3 and Alycone, as well as the results from the pivotal study of selinexor with dexamethasone in penta-refractory MM and the first reports on the effect of melflufen treatment on progression free survival.

ASH 2018 | Practice changing abstracts in multiple myeloma

If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the Multiple Myeloma Hub resource below

Download Here
  1. #301: Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

    https://multiplemyelomahub.com/medical-information/ash-2018-ixazomib-maintenance-for-patients-with-newly-diagnosed-multiple-myeloma-results-from-the-tourmaline-mm3-trial
  2. #126: VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

    https://multiplemyelomahub.com/medical-information/long-term-follow-up-of-the-gem05menos65-clinical-trial-for-newly-diagnosed-multiple-myeloma
  3. #156: One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

    https://ash.confex.com/ash/2018/webprogram/Paper113183.html
  4. #LBA-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

    https://multiplemyelomahub.com/medical-information/daratumumab-triplet-regimen-as-a-frontline-treatment-for-multiple-myeloma-patients-non-eligible-for-asct-interim-results-of-the-maia-trial 
  5. #598: Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta Exposed and Triple Class-Refractory MM

    https://ash.confex.com/ash/2018/webprogram/Paper116663.html
  6. #600 OP-106: Horizon - Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

    https://ash.confex.com/ash/2018/webprogram/Paper113095.html

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox